Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma.

Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, Tirosh I, Reuben A, Patkar S, Levy R, Quinkhardt J, Omokoko T, Qutob N, Golani O, Zhang J, Mao X, Song X, Bernatchez C, Haymaker C, Forget MA, Creasy C, Greenberg P, Carter BW, Cooper ZA, Rosenberg SA, Lotem M, Sahin U, Shakhar G, Ruppin E, Wargo JA, Friedman N, Admon A, Samuels Y.

Cancer Discov. 2018 Sep 12. doi: 10.1158/2159-8290.CD-17-1418. [Epub ahead of print]

PMID:
30209080
2.

The bone marrow is patrolled by NK cells that are primed and expand in response to systemic viral activation.

Milo I, Blecher-Gonen R, Barnett-Itzhaki Z, Bar-Ziv R, Tal O, Gurevich I, Feferman T, Drexler I, Amit I, Bousso P, Shakhar G.

Eur J Immunol. 2018 Jul;48(7):1137-1152. doi: 10.1002/eji.201747378. Epub 2018 May 2.

PMID:
29624673
3.

Lung Injury Repair by Transplantation of Adult Lung Cells Following Preconditioning of Recipient Mice.

Milman Krentsis I, Rosen C, Shezen E, Aronovich A, Nathanson B, Bachar-Lustig E, Berkman N, Assayag M, Shakhar G, Feferman T, Orgad R, Reisner Y.

Stem Cells Transl Med. 2018 Jan;7(1):68-77. doi: 10.1002/sctm.17-0149. Epub 2017 Dec 20.

4.

Culturing CTLs under Hypoxic Conditions Enhances Their Cytolysis and Improves Their Anti-tumor Function.

Gropper Y, Feferman T, Shalit T, Salame TM, Porat Z, Shakhar G.

Cell Rep. 2017 Sep 12;20(11):2547-2555. doi: 10.1016/j.celrep.2017.08.071.

5.

Active dissemination of cellular antigens by DCs facilitates CD8+ T-cell priming in lymph nodes.

Gurevich I, Feferman T, Milo I, Tal O, Golani O, Drexler I, Shakhar G.

Eur J Immunol. 2017 Oct;47(10):1802-1818. doi: 10.1002/eji.201747042.

6.

IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis.

Maurer M, Bougoin S, Feferman T, Frenkian M, Bismuth J, Mouly V, Clairac G, Tzartos S, Fadel E, Eymard B, Fuchs S, Souroujon MC, Berrih-Aknin S.

Acta Neuropathol Commun. 2015 Jan 15;3:1. doi: 10.1186/s40478-014-0179-6.

7.

Experimental myasthenia gravis in Aire-deficient mice: a link between Aire and regulatory T cells.

Aricha R, Feferman T, Berrih-Aknin S, Fuchs S, Souroujon MC.

Ann N Y Acad Sci. 2012 Dec;1275:107-13. doi: 10.1111/j.1749-6632.2012.06843.x. Review.

PMID:
23278585
8.

Regulatory T cell-based immunotherapies in experimental autoimmune myasthenia gravis.

Souroujon MC, Aricha R, Feferman T, Mizrachi K, Reuveni D, Fuchs S.

Ann N Y Acad Sci. 2012 Dec;1274:120-6. doi: 10.1111/j.1749-6632.2012.06844.x.

PMID:
23252906
9.

The susceptibility of Aire(-/-) mice to experimental myasthenia gravis involves alterations in regulatory T cells.

Aricha R, Feferman T, Scott HS, Souroujon MC, Berrih-Aknin S, Fuchs S.

J Autoimmun. 2011 Feb;36(1):16-24. doi: 10.1016/j.jaut.2010.09.007. Epub 2010 Oct 29.

PMID:
21035305
10.

Involvement of phosphodiesterases in autoimmune diseases.

Mizrachi K, Aricha R, Feferman T, Kela-Madar N, Mandel I, Paperna T, Miller A, Ben-Nun A, Berrih-Aknin S, Souroujon MC, Fuchs S.

J Neuroimmunol. 2010 Mar 30;220(1-2):43-51. doi: 10.1016/j.jneuroim.2009.12.012. Epub 2010 Jan 25.

PMID:
20100627
11.

Suppression of experimental autoimmune myasthenia gravis by inhibiting the signaling between IFN-gamma inducible protein 10 (IP-10) and its receptor CXCR3.

Feferman T, Aricha R, Mizrachi K, Geron E, Alon R, Souroujon MC, Fuchs S.

J Neuroimmunol. 2009 Apr 30;209(1-2):87-95. doi: 10.1016/j.jneuroim.2009.01.021. Epub 2009 Feb 20.

PMID:
19232748
12.

Suppression of experimental autoimmune myasthenia gravis by combination therapy: pentoxifylline as a steroid-sparing agent.

Menon RT, Feferman T, Aricha R, Souroujon MC, Fuchs S.

J Neuroimmunol. 2008 Sep 15;201-202:128-35. doi: 10.1016/j.jneuroim.2008.05.023. Epub 2008 Jul 15. Erratum in: J Neuroimmunol. 2009 Oct 30;215(1-2):129.

PMID:
18632163
13.

Immunosuppression of EAMG by IVIG is mediated by a disease-specific anti-immunoglobulin fraction.

Fuchs S, Feferman T, Meidler R, Margalit R, Sicsic C, Brenner T, Laub O, Souroujon MC.

Ann N Y Acad Sci. 2008;1132:244-8. doi: 10.1196/annals.1405.032.

PMID:
18567875
14.
15.

Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis.

Aricha R, Feferman T, Fuchs S, Souroujon MC.

J Immunol. 2008 Feb 15;180(4):2132-9.

16.

A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis.

Fuchs S, Feferman T, Meidler R, Margalit R, Sicsic C, Wang N, Zhu KY, Brenner T, Laub O, Souroujon MC.

J Neuroimmunol. 2008 Feb;194(1-2):89-96. doi: 10.1016/j.jneuroim.2007.11.020. Epub 2008 Feb 21.

PMID:
18178258
17.

Suppression of experimental autoimmune myasthenia gravis by intravenous immunoglobulin and isolation of a disease-specific IgG fraction.

Fuchs S, Feferman T, Zhu KY, Meidler R, Margalit R, Wang N, Laub O, Souroujon MC.

Ann N Y Acad Sci. 2007 Sep;1110:550-8.

PMID:
17911471
18.

DNA microarray in search of new drug targets for myasthenia gravis.

Feferman T, Aricha R, Menon R, Souroujon MC, Berrih-Aknin S, Fuchs S.

Ann N Y Acad Sci. 2007 Jun;1107:111-7.

PMID:
17804538
19.

Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms.

Zhu KY, Feferman T, Maiti PK, Souroujon MC, Fuchs S.

J Neuroimmunol. 2006 Jul;176(1-2):187-97. Epub 2006 May 26.

PMID:
16730380
20.

Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor.

Aricha R, Feferman T, Souroujon MC, Fuchs S.

FASEB J. 2006 Feb;20(2):374-6. Epub 2005 Dec 19.

PMID:
16365386
21.

Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis.

Feferman T, Maiti PK, Berrih-Aknin S, Bismuth J, Bidault J, Fuchs S, Souroujon MC.

J Immunol. 2005 May 1;174(9):5324-31.

22.

Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment.

Maiti PK, Feferman T, Im SH, Souroujon MC, Fuchs S.

J Neuroimmunol. 2004 Jul;152(1-2):112-20.

PMID:
15223243
23.

Suppression of myasthenia gravis by antigen-specific mucosal tolerance and modulation of cytokines and costimulatory factors.

Souroujon MC, Maiti PK, Feferman T, Im SH, Raveh L, Fuchs S.

Ann N Y Acad Sci. 2003 Sep;998:533-6.

PMID:
14592924
24.

Epitope spreading to hidden cytoplasmic regions of the acetylcholine receptor in experimental autoimmune myasthenia gravis.

Feferman T, Im SH, Fuchs S, Souroujon MC.

Ann N Y Acad Sci. 2003 Sep;998:388-90. No abstract available.

PMID:
14592902
25.

Breakage of tolerance to hidden cytoplasmic epitopes of the acetylcholine receptor in experimental autoimmune myasthenia gravis.

Feferman T, Im SH, Fuchs S, Souroujon MC.

J Neuroimmunol. 2003 Jul;140(1-2):153-8.

PMID:
12864983
26.

Protective molecular mimicry in experimental myasthenia gravis.

Im SH, Barchan D, Feferman T, Raveh L, Souroujon MC, Fuchs S.

J Neuroimmunol. 2002 May;126(1-2):99-106.

PMID:
12020961
27.

Supplemental Content

Loading ...
Support Center